Supply agreement SARS-CoV-2 mRNA Vaccine

Concepts

• vaccines
• sars
• procurement of the mrna-1273 vaccine
• vaccine vendors
• supply agreement sars-cov-2 mrna vaccine
• fair competition
• national governments
• commercial sensitivity
• competitors
• reg

Location

United Kingdom:

Description

The procurement of the mRNA-1273 vaccine.

Total Quantity or Scope

Additional information: Contract value is being withheld due to commercial sensitivity (Reg 50(6)(b) and (c)). Publication may enable competitors to calculate cost per dose. This will commercially prejudice: (i) the supplier in its negotiations with other national governments; and (ii) the contracting authority in negotiations with other vaccine vendors. It may also impact fair competition between vaccine vendors.

Award Detail

Award Criteria

CPV Codes

• 33651600 - Vaccines

Legal Justification

The award of the contract to Moderna is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to find a viable vaccine to end the Covid-19 pandemic (Regulation 32(2)(c)).

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** Contract end date is being withheld on grounds that release would be contrary to public interest (Reg 50(6)(a)) and commercial sensitivity (Reg 50(6)(b) and (c)). The date is variable based on production and delivery. Given significant challenges to overcome, the end date may set unrealistic expectation for the public/market.